Christopher Ogden, the chief financial officer at CytomX Therapeutics, Inc. (NASDAQ:CTMX), sold 19,323 shares of the company’s common stock on March 17, 2026. The sale was executed at a price of $6.423 per share and generated total proceeds of $124,111. Company filings show the disposition was carried out to satisfy tax obligations related to the vesting of restricted stock units.
Following the transaction, Ogden directly holds 296,948 shares of CytomX common stock. That total includes 173,082 restricted stock units that remain part of his holdings.
The $6.423 sale price represented a notable premium to CytomX’s prevailing share price of $4.78 at the time of reporting, a gap the company’s recent trading volatility helped create. Despite near-term weakness in the share price, CytomX has recorded a substantial 613% return over the past year, and the company’s market capitalization stands at $951 million.
Corporate financing and analyst updates
Separately from the insider sale, CytomX priced an underwritten public offering of 45,990,567 shares of common stock at $5.30 per share, a transaction intended to raise approximately $250 million in gross proceeds. The offering includes an option for underwriters to acquire up to an additional $37.5 million of common stock, exercisable depending on market conditions. Company statements indicate the offering is geared toward supporting development of its drug pipeline.
On the research front, Jefferies raised its price target for CytomX to $16.00 from $8.00 and maintained a Buy rating after noting promising Phase 1a data for the company’s EpCAM antibody-drug conjugate. Oppenheimer also increased its price target to $12.00 from $10.00, citing positive trial data for the CX-2051 program.
During CytomX’s Q4 2025 earnings call, management highlighted clinical progress for the company’s lead candidate, Varseta-M, although the company did not disclose specific financial metrics on the call.
Summary
Ogden’s sale was a tax-driven disposition of 19,323 shares that left him with 296,948 shares of CytomX stock including RSUs. The company concurrently launched a sizable equity offering to finance its pipeline and received analyst target increases following encouraging early clinical data.
Key points
- Insider transaction: CFO Christopher Ogden sold 19,323 shares on March 17, 2026 at $6.423 per share, totaling $124,111, to cover RSU-related taxes.
- Financing move: CytomX priced 45,990,567 shares at $5.30 to raise $250 million, with an underwriter option for an additional $37.5 million, aimed at supporting drug development.
- Analyst reaction and clinical signals: Jefferies and Oppenheimer raised price targets following positive Phase 1a and CX-2051 data; the company emphasized Varseta-M clinical progress during its Q4 2025 call.
Risks and uncertainties
- Share-price volatility: The sale price was materially higher than the reported market price of $4.78, reflecting recent stock volatility that may affect investor sentiment in the biotech sector.
- Dilution risk: The large public offering of common stock, intended to raise $250 million, could dilute existing shareholders depending on final subscription and underwriter participation, impacting capital markets and equity holders.
- Clinical and disclosure uncertainty: While management noted clinical progress for Varseta-M, specific financials were not disclosed, and ongoing clinical development remains an uncertainty for the company and investors in the healthcare sector.